BSHI and BTS UK guideline on the detection of alloantibodies in solid organ (and islet) transplantation
Richard Battle, Deborah Pritchard, Sarah Peacock, C. Hastie, Judith Worthington, Sue Jordan, Jennifer A McCaughlan, Martin Barnardo, Rebecca Cope, Claire Collins, Natalia Diaz‐Burlinson, Carla Rosser, Luke Foster, Delordson Kallon, Olivia Shaw, David Briggs, David M. Turner, Arthi Anand, Arash Akbarzad‐Yousefi, Deborah Sage
Abstract
Solid organ transplantation represents the best (and in many cases only) treatment option for patients with end-stage organ failure. The effectiveness and functioning life of these transplants has improved each decade due to surgical and clinical advances, and accurate histocompatibility assessment. Patient exposure to alloantigen from another individual is a common occurrence and takes place through pregnancies, blood transfusions or previous transplantation. Such exposure to alloantigen's can lead to the formation of circulating alloreactive antibodies which can be deleterious to solid organ transplant outcome. The purpose of these guidelines is to update to the previous BSHI/BTS guidelines 2016 on the relevance, assessment, and management of alloantibodies within solid organ transplantation.